medigraphic.com
ISSN 2007-6800 (Print)

2017, Number 2

<< Back

Rev Mex Traspl 2017; 6 (2)

Membranous nephropathy as a cause of nephrotic syndrome post renal transplantation

Pazarín-Villaseñor L, Villanueva-Pérez A, Ortiz-López CR

Language: Spanish
References: 40
Page: 75-80
PDF size: 343.43 Kb.


ABSTRACT

In Mexico there is a significant increase in the incidence and prevalence of chronic kidney disease with the subsequent increase in the practice of renal transplantation throughout the country, which leads to a greater number of complications associated with this procedure. These complications include glomerulopathies following renal transplantation. In particular, membranous nephropathy is one of the most common glomerular diseases. This pathology is most often associated with the appearance of proteinuria in the nephrotic range at the post-transplant stage, which represents a poor prognostic factor for the patient’s life and graft function. Failure to know the cause of primary kidney disease makes it difficult to determine whether it is a recurrence of the underlying disease or a de Novo nephropathy. In the present work, the case of a woman with proteinuria in nephrotic ranges after being transplanted and with an adequate evolution after the immunosuppressive treatment, is reviewed.


REFERENCES

  1. Garcia-Garcia G, Briseño-Renteria G, Luquín-Arellan VH, Gao Z, Gill J, Tonelli M. Survival Among patients with kidney failure in Jalisco México. J Am Soc Nephrol. 2007; 18 (6): 1922-1927.

  2. US Renal Data System: 2013 Atlas of End Stage Renal Disease in the United States. International Comparisons. Available at: http://www.usrds.org/atlas.htm acceded January 20, 2014.

  3. KDIGO 2012; Summary of Recommendation Statements; KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013; 3(1): 5-14.

  4. Cueto-Manzano AM, Quintana-Piña E, Correa-Rotter R. Long term CAPD survival and analysis of mortality risk factors: 12-year experience of a single mexican center. Perit Dial Int. 2001; 21: 148-153.

  5. Cueto-Manzano AM, Rojas-Campos E. Status of renal replacement therapy and peritoneal dialysis in Mexico. Perit Dial Int. 2007; 27: 142-148.

  6. García GG, Harden P, Chapman J. El papel global del trasplante renal. Nefrologia. 2012; 32 (1): 1-6.

  7. Oriol B, Martorell J, Cruzado JM, Grinyo J. Inmunobiología del trasplante renal y bases del tratamiento inmunosupresor. En: L. Hernando Avendaño. Nefrología clínica. 3ra edición, Editorial Panamericana; 2009, 971-986.

  8. Seron-Micas D, Moreso-Mateos F. Disfunción crónica tardía del trasplante; Nefrología al día; [Consultado el 20 de septiembre 2014] Disponible en: http://www.nefrologiadigital.revistanefrologia.com/publicaciones/P1E13/cap-47.pdf.

  9. Gondos A, Dohler B, Brenner H, Opelz G. Kidney graft survival in Europe and the united states; strikingly different long-term outcomes. Transplantation. 2013; 95: 267-274.

  10. Moreso F, Alonso A, Gentil MA, González-Molina M, Capdevila L, Marcén R et al. Improvement in late allograft survival between 1990 and 2002 in Spain: Results from a multicenter case-control study. Transplant Int. 2010; 23 (9): 907-913.

  11. Reyes I, Calleja C, González A. Experiencia de ocho años en reportes de biopsias renales en el Servicio de Patología del Hospital de Especialidades Centro Médico “La Raza”. Nefrología Mexicana. 2001; 22 (3): 156-157A.

  12. Ramos F, Ornelas G, Zuñiga R y cols. Epidemiología de la enfermedad glomerular en México. Nefrología Mexicana. 2001; 22 (3): 157A.

  13. Malafronte P, Mastroianni-Kirsztajn G, Betônico GN, Romão JE Jr, Alves MA, Carvalho MF et al. Paulista registry of glomerulonephritis: 5 years data report. Nephrol Dial Transplant. 2006; 21: 3098-3105.

  14. Arias LF, Henao J, Giraldo RD, Carvajal N, Rodelo J, Arbelaez M. Enfermedades glomerulares en una población hispánica: resultados de un registro regional de biopsias renales. Sao Paulo Med J. 2009; 127 (3): 140-144.

  15. Bertolatus JA, Hunsicker LG. Recurrent and de novo glomerular disease in renal trasplants. In: Neilson EG, Couser WG, eds. Inmunologic renal diseases. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 1225-1246.

  16. Berger BE, Vicenti F, Biava C, Amend WJ Jr, Feduska N, Salvatierra O Jr. De novo and recurrent membranous glomerulopathy following kidney trasplantation. Trasplantation. 1983; 21 (4): 315-319.

  17. Charpentier B, Hiesse C, Marchand S, Boubenider S, Durrbach A, Kriaa F. De novo and recurrent diseases: recurrent glomerulopathies. Trasplant Proc. 1999; 31: 264-266.

  18. Salazar MA, Paez H, Ramos F, Rojas-Campos E, Monteon F. Glomerulonefritis Membranosa Postrasplante en una Unidad de Alta Especialidad en el Occidente del País. Nefrología Mexicana. 2004; 25 (3): 114A.

  19. Aguilar-Fletes L, Martinez-Garcia O, Segura-Trujillo M y cols. Hallazgos de la biopsia renal en pacientes trasplantados del Centro Médico Nacional de Occidente: Reporte de los últimos 7 años. Nefrología Mexicana. 2007; 28 (3): 89-90A.

  20. Ponticelli C, Moroni G, Glassock RJ. De novo renal disease after renal transplantation. Clin J Am Soc Nephrol. 2014; 9: 1479-1487.

  21. Park JH, Park JH, Bok HJ, Kim BS, Yang CW, Kim YS et al. Persistent proteinuria as a pronostic factor for determining long-term graft survival in renal transplant recipients. Transplant Proc. 2000; 33 (7): 1924.

  22. Knoll GA. Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management. Am J Kidney Dis. 2009; 54 (6): 1131-1144.

  23. Merino-Lopez M, Morales-Buenrrostro. Enfermedades glomerulares recurrentes en trasplamte renal. Revista Mexicana de Trasplantes. 2013; 2 (2): 64-72.

  24. Amer H, Fidler ME, Myskak M, Morales P, Kremers WK, Larson TS et al. Proteinuria after Kidney Transplantation, Relationship to Allograft Histology and survival. Am J Transplant. 2007; 7: 2748-2756.

  25. Sancho A, Gavela E, Avila A, Morales A, Fernández-Nájera JE, Crespo JF et al. Risk factors and prognosis for proteinuria in renal transplant recipients. Transplant Proc. 2007; 39: 2145-2147.

  26. Monteón FJ, Gómez B, Valdespino C, Chávez S, Sandoval M, Flores A et al. The Kidney Transplant Experience at Hospital Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Mexico. Clin Transpl. 2003; 165-174.

  27. Cueto-Manzano A, Rojas-Campos E, Rosales G, Gómez B, Martínez HR, Cortés-Sanabria L et al. Risk factors for long-term graft loss in kidney transplantation: experience of a Mexican single center. Rev Invest Clin. 2002; 54 (6): 492-496.

  28. Cañas L, López D, Pérez JF, Bancu I, Juega J, Ariza A et al. Recurrent glomerulonephritis in renal transplantation: experience in our renal transplantation center. Transplant Proc. 2015; 47: 2354-2356.

  29. Broecker V, Mengel M. The significance of histological diagnosis in renal allograft biopsies in 2014. Transplant Int. 2015; 28: 136-143.

  30. Yakupoglu U, Baranowsca-Daca E, Rosen D, Barrios R, Suki WN, Truong LD. Post-transplant nephrotic syndrome comprehensive clinicopathologic study. Kidney Int. 2004; 65: 2360-2370.

  31. Keraney N, Podolak J, Matsumura L, Houghton D, Troxell M. Patterns of IgG subclass deposits in membranous glomerulonephritis in renal allografts. Transplant Proc. 2011; 43: 3743-3746.

  32. Larsen CP, Walker PD. Phospholipase A2 receptor (PLA2R) staining is useful in determination of the novo versus recurrent membranous glomerulopathy. Transplantation. 2013; 95: 1259-1262.

  33. Debiec H, Martin L, Jounneau C, Dautin G, Mesnard L, Rondeau E et al. Autoantibodies specific for the lipase A2 receptor in recurrent and the novo membranous nephropathy. Am J Transplant. 2011; 11: 2144-2152.

  34. Beck LH. Monoclonal anti-PLA2R and rrecurrent membranous nephropathy: another piece on the puzzle. J Am Soc Nephrol. 2012; 23: 1911-1913.

  35. Kattath A, Ayalon R, Beck LH, Sethi S, Sandor DG, Cosio FG et al. Antiphospholipase A2 receptor antibodies in recurrent membranous nephropathy. Am J Transplant. 2015; 15 (5): 1349-1359.

  36. Truoung L, Gelfand J, D’Agati V, Tomaszewski J, Appel G, Hardy M et al. De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature. Am J Kidney Dis. 1989; 14: 131-144.

  37. Swartz A, Kraus PH, Oferman G, Keller F. Recurrent and the Novo renal disease after kidney transplantation with or without ciclosporine A. Am J Kidney Dis. 1991; 17: 524-531.

  38. Muirhead N. Management of idiopathic membranous nephropathy: Evidence-based recommendations. Kidney Int. 1999; 55 (Supp 70): S47-55.

  39. Poduval RD, Josephson MA, Javaid B. Treatment of de novo and recurrent membranous nephropaty in renal transplant patients. Semin Nephrol. 2003; 23 (4): 392-399.

  40. Honda K, Horita S, Toki D, Taneda S, Nitta K, Hattori M et al. De novo membranous nephropathy and antibody-mediated rejection in transplanted kidney. Clin Transplant. 2011; 205: 191-200.




2020     |     www.medigraphic.com